Cervical cancer (CC) is responsible for higher morbidity and mortality in the world. To understand the pharmacologic drugs' efficacy in CC therapy, we investigated the ability of some widely used or potential anti-cancer drugs (alpha-naphthoflavone (ANF), betanaphthoflavone (BNF), clotrimazole (CLO), dimethoxybenzoquinone (DMB), paclitaxel (PAC), rifampicin (RIF), and RU-486) to agonize or antagonize with nuclear receptors: aryl hydrocarbon receptors (AhR) and pregnane X receptors (PXR). To achieve this goal, we performed our study on positive transfected HeLa cell lines, a representative cell line model for CC. In this paper, a study of the recent patents for the importance of these drugs as AhR or PXR agonists or antagonists was evaluated. However, we demonstrated that ANF and PAC were found to agonize the AhR-mediated transcription in a dose-dependent manner. We reported also that PAC and RIF induced PXR, a strong agonist activity. Antagonistic activities toward AhR and PXR were shown only in BNF. Because little is known about the implication of AhR and PXR in cancer therapy, our results could be helpful for the design of future CC therapeutics. Future studies could lead to a better understanding of AhR and PXR transactivation/inhibition implication in CC; and lead to a better knowledge of CC therapy.
INTRODUCTION

RESULTS
To better define the affinity/activity of some anti-cancer drugs to AhR or PXR, we performed in vitro AhR and PXR assays on AhR-positive cell line: AhRE 
